ABOUT: Welcome to CRWENewswire, Stocks to Watch for Thursday November 17th, 2011. I am Shalika Jayasekera. On its Fourth quarter fiscal 2011, ZOLL Medical Corp - symbol ZOLL - posted Record revenues of $151.9 million, a 26% increase year over year, and Net income of $11.9 million, increased 65% compared to the same period the prior year. Alnylam Pharmaceuticals Inc - symbol ALNY - has granted to Sylentis, S.A. a non-exclusive option for a new target-specific InterfeRx license. Upon Sylentis’ exercise of this option, Alnylam would receive upfront and milestone payments, as well as royalties on sales of products covered by the licensing agreement. and finally; Incyte Corp - symbol INCY - reported that the FDA has granted marketing approval for Jakafi for the treatment of patients with intermediate or high-risk myelofibrosis. Jakafi is the first and only product to be approved by the FDA for Myelofibrosis.